nference study flags need to monitor frailty risks with GLP-1 drugs for older adults

nference study suggest that some people can keep the weight off.

Does stopping a GLP-1 really doom you to regain all the weight?

Harness diverse real-world data types to gain insights across genomic, clinical, and operational dimensions

Data Modality

nference’s platform and tools transform real world data into actionable insights for healthcare innovation.

Join leaders across biopharma, clinical research, data science, and healthcare to explore how AI is advancing immunology research—from decoding complex disease biology to accelerating evidence generation and improving translational decision-making.

Join our upcoming events to explore the latest industry trends, discover technological breakthroughs, and gain expert insights. Network with leaders and stay at the forefront of healthcare innovation.

Streamline research with AI-powered tools that transform complex data into actionable medical insights

For Clinical Researchers

Access advanced datasets and cutting-edge analytics to power innovation in healthcare and life sciences.

For Data Scientists

nSights turns complex healthcare data into actionable insights, driving innovation and smarter decision-making in medical research and development.

Revolutionize drug development through AI-driven insights, accelerating timelines and improving clinical trial outcomes.

For Bio Pharma

Unlock actionable insights to improve patient outcomes and optimize healthcare delivery with data-driven solutions.

For Health Systems

Our AI-driven solutions empower clinical trial design, enhance innovation in product development and streamline regulatory submissions.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and tirzepatide have transformed obesity care and weight management, delivering unprecedented levels of weight loss in real-world practice.

What happens to weight after we stop prescribing GLP-1 therapies?

Characterization of Patients With Narcolepsy Treated vs Not Treated With Sodium Oxybate: A Propensity Score–Matched Cohort Study

Associations of the Fibrosis-4 Index With Rates of Cardiac Events and Liver Decompensation, and the Potential Implications on Risk Stratification in Patients With Nonalcoholic Steatohepatitis.

nference's extensive library of publications showcase cutting-edge research and healthcare advancements.

Blogs

nference Establishes AI Initiative with Takeda to Advance Precision Medicine in Inflammatory Bowel Disease

News

Our latest blogs and insights cover industry trends, technological breakthroughs, and expert insights, to keep you updated on the forefront of healthcare innovation.

Cutting-edge AI solutions to transform cardiac care

Empowering digital pathology with a new WSI paradigm